Labriola Laura, Pochet Jean-Michel
Department of Nephrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels - Belgium.
J Vasc Access. 2017 Mar 6;18(Suppl. 1):34-38. doi: 10.5301/jva.5000681. Epub 2017 Mar 5.
The prevention of catheter-related blood stream infections (CRBSI) in hemodialysis (HD) patients remains a challenge because of high morbidity and mortality associated to CRBSI. Alternative locking solutions (ALS) containing an antithrombotic substance with additional antimicrobial or antibiofilm properties (citrate, ethylenediaminetetraacetic acid [EDTA], 70% ethanol, thrombolytics) with or without the addition of molecules with specific antimicrobial activity (antibiotics, taurolidine, paraben-methylene-blue) has been proposed with the aim to prevent or eradicate intraluminal biofilm colonization and subsequent CRBSI. In this review, we examine the available evidence concerning their efficacy and potential side effects, in order to determine whether ALS should be implemented widely or only in selected cases.
由于与导管相关的血流感染(CRBSI)相关的高发病率和死亡率,预防血液透析(HD)患者的CRBSI仍然是一项挑战。已提出使用含有具有额外抗菌或抗生物膜特性的抗血栓物质(柠檬酸盐、乙二胺四乙酸[EDTA]、70%乙醇、溶栓剂)的替代封管溶液(ALS),无论是否添加具有特定抗菌活性的分子(抗生素、牛磺罗定、对羟基苯甲酸甲酯-亚甲蓝),其目的是预防或根除管腔内生物膜定植及随后的CRBSI。在本综述中,我们研究了有关其疗效和潜在副作用的现有证据,以确定ALS是否应广泛应用或仅在特定病例中应用。